AbCellera Biologics Inc.(ABCL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

AbCellera Biologics Inc. (ABCL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABCL at 29.3/100 on a 32-signal composite quality model, placing it at rank #2,534 of 2,961 stocks — the bottom half of the AI-ranked universe. ABCL scores in the top quartile across revenue growth (91.5). Areas of concern include free cash flow (4.8) and profitability (4.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AbCellera Biologics Inc. reports quarterly revenue of $4.0M, net income of $-55.4M, free cash flow of $23.8M. Top institutional holders of ABCL by reported 13-F value include BAKER BROS. ADVISORS, Capital World Investors, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. ABCL trades on the Nasdaq exchange and files with the SEC under CIK 1703057. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABCL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbCellera Biologics Inc. directly from SEC EDGAR.